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Clopidogrel resistance e A clear problem with an
unclear solutionSameer Bansilal, Deepak L. Bhatt*
VA Boston Healthcare System, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USAOver the last decade, dual antiplatelet therapy has been polymorphism and bleeding outcomes in their analysis.shown to be of significant benefit for secondary prevention in
millions of patients with acute coronary syndromes (ACS), in
those undergoing percutaneous coronary interventions (PCI),
and in those with atrial fibrillation unable to take warfarin.1e3
Much like any other therapeutic agent, variability in response
to clopidogrel was considered a reason for clinical failure
leading to cardiovascular events; it was not until the 2006
firestorm related to late stent thrombosis that this issue
underwent systematic study.4,5 Investigations into the phar-
macokinetic (PK) and pharmacodynamic (PD) properties of
clopidogrel led to the uncovering of specific genetic poly-
morphisms such as CYP2C19*2 and ABCB1 involved in the
metabolic conversion of the pro-drug clopidogrel into its
active metabolite which finally binds to the ADP receptor
responsible for the antiplatelet effect. Reduced function of
these alleles has since been shown to be associated with
impaired PK and PD response to clopidogrel andworse clinical
cardiovascular outcomes, with those homozygous for this
polymorphism faring worse than those who were heterozy-
gous, adding further biological plausibility.6e10 Given the large
numbersworldwidewho need to be on clopidogrel therapy for
various secondary prevention indications, even the conser-
vative prevalence estimates for these genetic polymorphisms
on the order of 25% make it a priority for clinical research.
The study by Singh et al published in this issue of the
Indian Heart Journal meta-analyzes 19,601 subjects from 14
studies and reaffirms the association between the CYP2C19*2
polymorphism carrier status and increased risk for major
adverse cardiovascular events (MACE e RR 1.28, CI 1.06e1.54;
P ¼ 0.009).11 The relation also holds for the risk of myocardial
infarction and stent thrombosis; however, these results need
to be interpreted in the context of significant heterogeneity
between studies with respect to these outcomes. There
appeared to be no relation between the CYP2C19*2* Corresponding author. 1400 VFW Parkway, Boston, MA 02132, USA.
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polymorphism carrier status and risk for future MACE or
bleeding outcomes. The authors attempt to put their
findings in perspective by providing sensitivity, specificity,
positive and negative predictive value parameters for genetic
testing. The high negative predictive value of genetic testing
for MACE of 92e99% is striking, while the low positive
predictive value of 3e10% is quite underwhelming. The
paper by Singh et al thus adds to the significant body of
existing literature regarding the importance of CYP2C19*2
polymorphisms and associated risk for cardiovascular events.
Previous large observational studies nested in mega-trials
have had similar findings, though with some notable differ-
ences. Simon et al studied 2,208 acute myocardial infarction
subjects in the FAST-MI trial (The French registry of Acute ST
elevation or non-ST elevationMyocardial Infarction), showing
that patients carrying any two of the CYP2C19 loss-of-function
polymorphisms had a significantly elevated 1-year MACE rate.
Amoderate associationwas also shown in the study forABCB1
carrier status andMACE.9 Mega et al evaluated CYP450 genetic
variants and their associations withMACE in 1,477 clopidogrel
treated subjects from the TRITON-TIMI 38 trial (TRial to assess
Improvement in Therapeutic Outcomes by optimizing platelet
InhibitioN with prasugrel). CYP2C19*2 carrier status was
associated with an elevated risk for MACE and stent
thrombosis, but not bleeding outcomes.7
While the risk associated with these CYP2C19 poly-
morphisms has clearly been defined, a clear solution has been
less forthcoming. Attempts at tailoring clopidogrel therapy
using a platelet function guided approach have not been
successful, as seen in the GRAVITAS and TRIGGER-PCI
trials.12,13 In the GRAVITAS trial (Gauging Responsiveness
with A VerifyNow assaydImpact on Thrombosis And Safety),
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platelet reactivity [P2Y (12) reaction units (PRU) 230] were
randomized to continue on the 75-mg clopidogrel dose or to
receive a 600-mg loading dose and a 150-mg maintenance
dose.12 At 6 months, the composite primary end point of
cardiovascular death/MI/stent thrombosis was identical in
both groups, at 2.3% using the predefined cutoff of 230 PRU.
This strategy was not associated with a significantly lower
risk of the primary end point at 60 days or at 6 months. A
post hoc look at a threshold of 208 PRU (informed by more
recent data from the 3T/2R14 and TRIGGER-PCI studies)
showed that patients with platelet reactivity below this
cutoff did have a lower risk of the primary end point both at
60 days and 6 months. In the TRIGGER-PCI trial (Testing
platelet reactivity in patients undergoing elective stent
placement on clopidogrel to guide alternative therapy with
prasugrel), stable coronary artery disease (CAD) patients
with high on-treatment platelet reactivity (>208 PRU by the
VerifyNow test) after elective PCI with at least one drug-
eluting stent (DES) were randomly assigned to either
prasugrel 10 mg daily or clopidogrel 75 mg daily. Platelet
reactivity of the patients on the study drug was reassessed
at 3 and 6 months. The study was stopped prematurely for
futility because of a lower than expected incidence of the
primary end point.13
The concept that lowering PRU or achieving adequate
platelet inhibition might be a dose issue receives mechanistic
credence from the ELEVATE TIMI-56 (Escalating Clopidogrel by
Involving a Genetic Strategy) study.15 Mega et al studied 333
patients who were genotyped and then received various
maintenance doses of clopidogrel depending on genotype for
four 14-day treatment periods. The 247 non-carriers of
a loss-of-function CYP2C19*2 allele received clopidogrel
doses of 75 mg and 150 mg daily (two periods each), while
the 86 carriers (80 heterozygotes, six homozygotes) received
doses of 75 mg, 150 mg, 225 mg, and 300 mg daily. At the
end of each study period, platelet function testing was
performed with both VASP and VerifyNow assays. When
treated with a standard clopidogrel maintenance dose of
75 mg daily, both CYP2C19*2 heterozygotes and homozygotes
had significantly higher on-treatment platelet reactivity than
did non-carriers. Among CYP2C19*2 heterozygotes, each 75-
mg increase in clopidogrel dose led to an approximate 8% to
9% absolute reduction in the platelet-reactivity index. At the
end of the study period, 52% of CYP2C19*2 heterozygotes
were non-responders (230 PRU) with 75 mg of clopidogrel,
while only 10% were non-responders with 225 or 300 mg
(P < 0.001 for both). In CYP2C19*2 homozygotes, even with
300 mg daily of clopidogrel, mean VASP PRI was 68.3% (95%
CI 44.9%e91.6%) and mean PRU was 287.0 (95% CI
170.2e403.8). Thus, among patients with stable
cardiovascular disease, tripling the maintenance dose of
clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes
achieved levels of platelet reactivity similar to that seen
with the standard 75-mg dose in non-carriers; in contrast,
for CYP2C19*2 homozygotes, doses as high as 300 mg daily
did not result in comparable degrees of platelet inhibition.
What remains to be shown, however, is translation of this
mechanistic benefit into reduction in clinical outcomes with
an acceptable bleeding risk in a large randomized trial.On the other hand, trials studying the efficacy of clopi-
dogrel versus placebo do not show any effect modification by
genotype. In the CHARISMA trial (Clopidogrel for High Athe-
rothrombotic Risk and Ischemic Stabilization, Management,
and Avoidance) which enrolled subjects with clinically
evident cardiovascular disease or multiple risk factors and
randomized them to clopidogrel versus placebo added on to
background therapy with aspirin, genotyping data was
examined in 4,819 subjects.16 Carriers of CYP2C19 loss-of-
function alleles did not have an increased rate of ischemic
events, but did have a significantly lower rate of any
bleeding (HR for bleeding: 0.80, 95% CI 0.69e0.93, P ¼ 0.003).
Similar results were seen in the analysis from the CURE/
ACTIVE genetic sub-study.17 Among 5,059 genotyped patients
with ACS in the CURE trial (Clopidogrel in Unstable Angina to
Prevent Recurrent Events), clopidogrel as compared with
placebo significantly reduced the rate of the primary efficacy
outcome, irrespective of the genetic polymorphism carrier
state (HR with clopidogrel for carriers, 0.69; 95% CI 0.49e0.98;
HR among non-carriers, 0.72; 95% CI 0.59e0.87). The effect of
clopidogrel on bleeding did not vary according to genotypic
subgroups. Among 1,156 genotyped patients with atrial
fibrillation in the ACTIVE trial (Atrial fibrillation clopidogrel
trial with irbesartan for prevention of vascular events), there
was no evidence of an interaction with respect to either
efficacy or bleeding outcomes between the study treatment
and the metabolizer phenotype, loss-of-function carrier
status, or gain-of-function carrier status. It follows from these
data that genotyping is not really useful if the choice is
between placebo and standard clopidogrel dosing.
Why the disconnect? As shown elegantly by Shuldiner
et al, the CYP2C19 polymorphisms are not associated with
baseline platelet aggregation or response to aspirin, but only
affect aggregation in response to clopidogrel.18 In addition, it
is possible that a proportion of the excess risk associated
with the polymorphism may be independent of clopidogrel
and may have to do with potential effects on the
metabolism of other cardiovascular drugs. Importantly, the
genetic polymorphisms explain only a small part of the
clopidogrel resistance story; drug compliance, body mass
index, diabetes, smoking, use of proton pump inhibitors, and
the presence of acute coronary syndromes all contribute to
the variability in clopidogrel effect.19
Given the current state of the data especially regarding
outcomes related to a genotyping strategy, we are in agree-
ment with the authors’ cautious optimism regarding the
larger uptake of genetic testing. One might argue that therapy
with ticagrelor or prasugrel has been clearly shown to be
superior to clopidogrel even in responders and data exist to
clearly demonstrate that both these drugs provide efficacious
platelet inhibition in carriers of the clopidogrel platelet resis-
tance polymorphisms.20,21 This then seems like the “easy”
solution to the clopidogrel variability problem. This easy
solution, however, carries a hefty price tag, especially when
one considers the generic availability of clopidogrel. Clopi-
dogrel will most likely continue to be a part of the antiplatelet
armamentarium for some time into the future and dose
titration or selective use, with the option to switch to more
potent agents when needed, may be a choice for the clinical
community.22 Availability of point of care rapid testing as
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Platelet Therapy Using an InDividualized Strategy Based on
GENetic Evaluation) may make this strategy feasible and
cost-effective.23 Large randomized, controlled trials will be
needed to validate the effectiveness and/or cost-
effectiveness of such an approach before routine use.
Meanwhile, as wisely concluded by the authors and
indicated in the ACC PCI guidelines, routine genetic testing
for clopidogrel resistance cannot be advised.24Disclosure
Dr. Deepak L. Bhatt discloses the following relationships e
Advisory Board: Medscape Cardiology; Board of Directors:
Boston VA Research Institute, Society of Chest Pain Centres;
Chair: American Heart Association Get With The Guidelines
Science Subcommittee; Honoraria: American College of
Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical
Research Institute (clinical trial steering committees), Slack
Publications (Chief Medical Editor, Cardiology Today Inter-
vention), WebMD (CME steering committees); Research
Grants: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai,
Ethicon, Medtronic, Sanofi Aventis, The Medicines Company;
Unfunded Research: FlowCo, PLx Pharma, Takeda. He was the
international Principal Investigator for the CHARISMA Trial
and the CHARISMA Genetics Study.r e f e r e n c e s
1. CAPRIE Steering Committee. A randomised, blinded, trial of
clopidogrel versus aspirin in patients at risk of ischaemic
events (CAPRIE). Lancet. 1996;348(9038):1329e1339.
2. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added
to aspirin in patients with atrial fibrillation. N Engl J Med.
2009;360(20):2066e2078.
3. Helton TJ, Bavry AA, KumbhaniDJ, Duggal S, RoukozH, BhattDL.
Incremental effect of clopidogrel on important outcomes in
patients with cardiovascular disease: a meta-analysis of
randomized trials.Am J Cardiovasc Drugs. 2007;7(4):289e297.
4. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel
resistance is associated with increased risk of recurrent
atherothrombotic events in patients with acute myocardial
infarction. Circulation. 2004;109(25):3171e3175.
5. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL,
Topol EJ. Variability in platelet responsiveness to clopidogrel
among 544 individuals. J Am Coll Cardiol. 2005;45(2):246e251.
6. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19
polymorphism in young patients treated with clopidogrel
after myocardial infarction: a cohort study. Lancet.
2009;373(9660):309e317.
7. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450
polymorphisms and response to clopidogrel. N Engl J Med.
2009;360(4):354e362.
8. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19
loss-of-function polymorphism and stent thrombosis
following percutaneous coronary intervention. Eur Heart J.
2009;30(8):916e922.
9. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic
determinants of response to clopidogrel and cardiovascular
events. N Engl J Med. 2009;360(4):363e375.
10. Trenk D, Hochholzer W, FrommMF, et al. Cytochrome P450
2C19 681G>A polymorphism and high on-clopidogrel plateletreactivity associated with adverse 1-year clinical outcome of
elective percutaneous coronary intervention with drug-eluting
or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925e1934.
11. Singh M, Shah T, Adigopula S, et al. CYP2C19*2/ABCB1-
C3435T Polymorphism and risk of Cardiovascular Events in
Coronary Artery Disease Patients on Clopidogrel: is clinical
testing helpful? Indian Heart J. 2012;64(4):341e352.
12. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose
clopidogrel based on platelet function testing after
percutaneous coronary intervention: the GRAVITAS
randomized trial. JAMA. 2011;305(11):1097e1105.
13. Trenk D, Stone GW, Gawaz M, et al. A Randomized Trial of
Prasugrel Versus Clopidogrel in Patients With High Platelet
Reactivity on Clopidogrel After Elective Percutaneous
Coronary Intervention With Implantation of Drug-Eluting
Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity
In Patients Undergoing Elective Stent Placement on
Clopidogrel to Guide Alternative Therapy With Prasugrel)
Study. J Am Coll Cardiol. 2012;59(24):2159e2164.
14. Valgimigli M, Campo G, de Cesare N, et al. Intensifying
platelet inhibition with tirofiban in poor responders to
aspirin, clopidogrel, or both agents undergoing elective
coronary intervention: results from the double-blind,
prospective, randomized Tailoring Treatment with Tirofiban
in Patients Showing Resistance to Aspirin and/or Resistance
to Clopidogrel study. Circulation. 2009;119(25):3215e3222.
15. Mega JL, Hochholzer W, Frelinger AL, et al. Dosing clopidogrel
based on CYP2C19 genotype and the effect on platelet
reactivity in patients with stable cardiovascular disease.
JAMA. 2011;306(20):2221e2228.
16. Bhatt DL, Pare G, Eikelboom JW, et al. The relationship
between CYP2C19 polymorphisms and ischaemic and
bleeding outcomes in stable outpatients: the CHARISMA
genetics study. Eur Heart J; 2012.
17. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype
on outcomes of clopidogrel treatment. N Engl J Med.
2010;363(18):1704e1714.
18. Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of
cytochrome P450 2C19 genotype with the antiplatelet effect
and clinical efficacy of clopidogrel therapy. JAMA.
2009;302(8):849e857.
19. Bhatt DL. Tailoring antiplatelet therapy based on
pharmacogenomics: how well do the data fit? JAMA.
2009;302(8):896e897.
20. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation
between CYP2C19 genotype and pharmacodynamics in
patients treated with ticagrelor versus clopidogrel: the
ONSET/OFFSET and RESPOND genotype studies. Circ
Cardiovasc Genet. 2010;3(6):556e566.
21. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1
and CYP2C19 and cardiovascular outcomes after treatment
with clopidogrel and prasugrel in the TRITON-TIMI 38 trial:
a pharmacogenetic analysis. Lancet.
2010;376(9749):1312e1319.
22. Kazi DS, Garber AM, Shah R, et al. Panacea or personalized
medicine? Optimizing antiplatelet therapy in acute coronary
syndrome e a cost-effectiveness analysis. J Am Coll Cardiol.
2012;59(13):E348.
23. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic
testing for personalisation of antiplatelet treatment (RAPID
GENE): a prospective, randomised, proof-of-concept trial.
Lancet. 2012;379(9827):1705e1711.
24. Holmes Jr DR, Dehmer GJ, Kaul S, Leifer D, O’Gara PT,
Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to
the FDA “boxed warning”: a report of the American College of
Cardiology Foundation Task Force on Clinical Expert
Consensus Documents and the American Heart Association.
Circulation. 2010;122(5):537e557.
